The Phase III randomized NEJ026 trial evaluated first-line erlotinib plus the VEGF inhibitor bevacizumab versus erlotinib alone in patients with EGFR-mutated advanced nonsquamous NSCLC [27]. Here, EGFR is linked to non-small cell lung carcinoma.